CJC-1295 with DAC vs without: what the complex changes

This is one of the most confused naming situations in the field, and a lot of that confusion is sold rather than accidental. Here is what actually separates the two, for material supplied for laboratory research use only.

DAC is a chemical addition, not a grade

DAC stands for Drug Affinity Complex. It is a maleimido-propionic acid group attached to the peptide, and its function is to bind covalently to serum albumin — the most abundant protein in blood plasma.

That is the entire mechanism, and everything else follows from it. Albumin circulates for a long time. A molecule bound to albumin is carried along with it and is not cleared on its own schedule. So the addition of DAC does not change what the peptide binds to at its receptor; it changes how long the molecule persists before clearance.

This is a well-established pharmaceutical technique and it is not unique to this compound. It is not a purity grade, not a quality tier, and not a brand name, and any seller presenting it as one has told you something.

The duration difference is not incremental

The two forms differ by orders of magnitude rather than by a margin. A GHRH analogue without albumin binding is cleared on the timescale of minutes; the DAC-modified version persists on the timescale of days.

That is why the two are studied in quite different experimental designs and why treating them as substitutes produces results that do not compare.

The naming problem, which is the real trap

Here is where the market misleads.

"CJC-1295 no DAC" is frequently not CJC-1295 at all. What is usually sold under that name is modified GRF (1-29) — sometimes written mod GRF (1-29) or sermorelin with substitutions — which is a related but distinct peptide. CJC-1295 as originally described is the DAC-bearing compound; the "no DAC" version is a different molecule that acquired the name by association.

So a listing offering both "with DAC" and "without DAC" is, in the ordinary case, offering two different peptides under one name. That is not necessarily dishonest — the usage is now so widespread that vendors inherit it — but it means the label alone does not establish what is in the container.

How to tell them apart on paper

They have different molecular masses. That is the check.

A laboratory report that identifies the compound rather than confirming what the client declared will produce a mass, and the mass distinguishes a DAC-bearing molecule from one without it. A report that lists only a purity percentage against a name the client supplied establishes nothing about which of the two you have.

This is the practical reason to care about how a report was produced, and it is covered in what a Janoshik report actually proves. Our own CJC-1295 DAC 10 mg is the DAC-bearing form, which is why the name carries the suffix rather than leaving it to be assumed.

The other GHRH analogues

CJC-1295 is not the only compound in this space. Tesamorelin is also a GHRH analogue and sits alongside it in the same anti-doping category. They are different molecules with different modifications and different regulatory histories — tesamorelin holds a US approval for a specific indication, and CJC-1295 does not hold one anywhere.

Both are prohibited under the WADA S2 category at all times, which is covered in which peptides are on the WADA prohibited list, and their approval status in FDA approved, MHRA licensed, or neither.

The other GHRH analogue in the range invites the obvious comparison, and the regulatory gap between them is wider than the chemical one: CJC-1295 vs tesamorelin.